IP Library › Granted Patent US 9,630,926
Granted Patent B2
US 9,630,926 · App. 15/184,968 · Granted Apr 25, 2017

Bendamustine derivatives and methods of using same

Inventors: Roger P. Bakale (Malvern, PA); Peter D. Brown (West Chester, PA); Jian Chen (West Chester, PA); Anthony S. Drager (Thorndale, PA); Rachel Y. LaBell (Coatesville, PA); Robert E. McKean (Chester Springs, PA); Piyush R. Patel (Wallingford, PA); Renee C. Roemmele (Maple Glen, PA)
Assignee: IGNYTA, INC.
C07D235/16A61K9/14A61K31/4184A61K47/42
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,630,926
App. No.
15/184,968
Granted
Apr 25, 2017
Kind
B2
Abstract

The present invention is directed to bendamustine esters and bendamustine amides and their use for the treatment of cancer.

Claims (20)

1. A compound of formula II:

wherein R 2 is C 1 -C 24 alkylene and R 3 is —COOC 1-3 alkyl; or R 2 -R 3 is C 8 -C 24 alkyl; or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , wherein R 2 -R 3 is C 10 -C 24 alkyl.

3. The compound of claim 1 , wherein R 2 -R 3 is C 12 -C 24 alkyl.

4. The compound of claim 1 , wherein R 2 -R 3 is C 14 -C 24 alkyl.

5. The compound of claim 1 , wherein R 2 -R 3 is C 16 -C 24 alkyl.

6. The compound of claim 1 , wherein R 2 -R 3 is C 18 -C 24 alkyl.

7. The compound of claim 1 , wherein R 2 -R 3 is C 10 alkyl.

8. The compound of claim 1 , wherein R 2 -R 3 is C 12 alkyl.

9. The compound of claim 1 , wherein R 2 -R 3 is C 14 alkyl.

10. The compound of claim 1 , wherein R 2 -R 3 is C 16 alkyl.

11. The compound of claim 1 , wherein R 2 is C 2 alkylene and R 3 is —COOCH 3 .

12. The compound of claim 1 , wherein the compound of formula II is

13. The compound of claim 1 , wherein the compound of formula II is

14. The compound of claim 1 , wherein the compound of formula II is

15. The compound of claim 1 , wherein the compound of formula II is

16. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier or diluent.

17. Nanoparticles comprising a compound according to claim 1 .

18. A method of treating cancer in a patient comprising administering to the patient a compound of formula II:

wherein R 2 is C 1 -C 24 alkylene; and R 3 is —COOC 1-3 alkyl; or R 2 -R 3 is C 8 -C 24 alkyl; or a pharmaceutically acceptable salt thereof.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 16, 2016
From: BAKALE, ROGER P.; CHEN, JIAN; DRAGER, ANTHONY S.; LABELL, RACHEL Y.; MCKEAN, ROBERT E.; PATEL, PIYUSH R.; ROEMMELE, RENEE C.
To: CEPHALON, INC.
Reel/Frame 039458/0678 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 16, 2016
From: BROWN, PETER D.; BAKALE, ROGER P.; CHEN, JIAN; DRAGER, ANTHONY S.; LABELL, RACHEL Y.; MCKEAN, ROBERT E.; PATEL, PIYUSH R.; ROEMMELE, RENEE C.
To: CEPHALON, INC.
Reel/Frame 039458/0687 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 16, 2016
From: CEPHALON, INC.
To: IGNYTA, INC.
Reel/Frame 039458/0705 →
Continuity (6)
Continuation 14868278 · Sep 28, 2015
Continuation 14699965 · Apr 29, 2015
Continuation PCTUS2013069550 · Nov 12, 2013
Provisional Application 61725213 · Nov 12, 2012
Provisional Application 61776951 · Mar 12, 2013
Related Publication 20160289198A1 · Oct 6, 2016